Regeneron $REGN says the FDA has rejected their application to sell a pre-filled syringe with Eylea, delaying a supplemental add-on that the biotech wants to safeguard its big blockbuster franchise from a rival. But the company was quick to spell out the reasons for the CRL, asserting that it can get things in line for regulators by early 2019.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,